Loss of the polycomb mark from bivalent promoters leads to activation of cancer-promoting genes in colorectal tumors

Cancer Research

Volumn 74, Issue 13, 2014, Pages 3617-3629

  Hahn, Maria A ^a   Li, Arthur X ^b   Wu, Xiwei ^a   Yang, Richard ^a   Drew, David A ^c   Rosenberg, Daniel W ^c   Pfeifer, Gerd P ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Information Sciences ^*  (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYCOMB GROUP PROTEIN;

ARTICLE; CANCER GROWTH; CHRONIC INFLAMMATION; COLON MUCOSA; COLORECTAL TUMOR; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA METHYLATION; EMBRYONIC STEM CELL; GENE ACTIVATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HISTONE MODIFICATION; HUMAN; HUMAN TISSUE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN TARGETING; TISSUE CHARACTERIZATION; ULCERATIVE COLITIS;

CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA METHYLATION; EPIGENETIC REPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; NEOPLASTIC STEM CELLS; POLYCOMB-GROUP PROTEINS; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC;

EID: 84904035110     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3147     Document Type: Article

References (51)

1. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128: 683-92.
2. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell 2013;153:38-55.
3. Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 2013;13:497-510.
4. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-58.
5. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011;6:479-507.
6. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008;9:465-76.
7. Rauch TA, Zhong X,Wu X, Wang M, Kernstine KH, Wang Z, et al. Highresolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci U S A 2008;105:252-7.
8. Berman BP, Weisenberger DJ, Aman JF, Hinoue T, Ramjan Z, Liu Y, et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet 2012;44:40-6.
9. Estecio MR, Issa JP. Dissecting DNA hypermethylation in cancer. FEBS Lett 2011;585:2078-86.
10. Bert SA, Robinson MD, Strbenac D, StathamAL, Song JZ, Hulf T, et al. Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell 2013;23:9-22.
11. Weichenhan D, Plass C. The evolving epigenome. Hum Mol Genet 2013;22:R1-6.
12. Putiri EL, Robertson KD. Epigenetic mechanisms and genome stability. Clin Epigenetics 2011;2:299-314.
13. Nagarajan RP, Fouse SD, Bell RJ, Costello JF. Methods for cancer epigenome analysis. Adv Exp Med Biol 2013;754:313-38.
14. Hughes LA, Melotte V, de Schrijver J, de Maat M, Smit VT, Bovee JV, et al. The CpG island methylator phenotype: what's in a name. Cancer Res 2013;73:5858-68.
15. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007;39:237-42.
16. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007;39:232-6.
17. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, et al. Epigenetic stem cell signature in cancer. Nat Genet 2007; 39:157-8.
18. Hahn MA, Hahn T, Lee DH, Esworthy RS, Kim BW, Riggs AD, et al. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res 2008;68:10280-9.
19. Rauch T, Li H, Wu X, Pfeifer GP. Mira-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res 2006;66:7939-47.
20. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, Lau SK, et al. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci U S A 2007;104:5527-32.
21. Simon JA, Kingston RE. Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. Mol Cell 2013;49:808-24.
22. Aloia L, Di Stefano B, Di Croce L. Polycomb complexes in stem cells and embryonic development. Development 2013;140:2525-34.
23. Kalari S, Pfeifer GP. Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet 2010; 70:277-308.
24. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin. Cancer Cell 2012;22:9-20.
25. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science 2013;339:1567-70.
26. Hahn MA, Qiu R, Wu X, Li AX, Zhang H, Wang J, et al. Dynamics of 5- hydroxymethylcytosine and chromatin marks in mammalian neurogenesis. Cell Rep 2013;3:291-300.
27. Hahn MA, Wu X, Li AX, Hahn T, Pfeifer GP. Relationship between gene body DNA methylation and intragenic H3K9me3 and H3K36me3 chromatin marks. PLoS ONE 2011;6:e18844.
28. WuX, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, et al. CpGisland hypermethylation in human astrocytomas. Cancer Res 2010;70: 2718-27.
29. Ooi SK, Qiu C, Bernstein E, Li K, Jia D, Yang Z, et al. Dnmt3l connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007;448:714-7.
30. Edwards JR, O'Donnell AH, Rollins RA, Peckham HE, Lee C, Milekic MH, et al. Chromatin and sequence features that define the fine and gross structure of genomic methylation patterns. Genome Res 2010;20:972-80.
31. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006;125:315-26.
32. Voigt P, Tee WW, Reinberg D. A double take on bivalent promoters. Genes Dev 2013;27:1318-38.
33. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008;40:741-50.
34. Gal-Yam EN, Egger G, Iniguez L, Holster H, Einarsson S, Zhang X, et al. Frequent switching of polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad SciUS A 2008;105:12979-84.
35. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007;449:1003-7.
36. van der Flier LG, van Gijn ME, Hatzis P, Kujala P, Haegebarth A, Stange DE, et al. Transcription factor achaete scute-like 2 controls intestinal stem cell fate. Cell 2009;136:903-12.
37. Stange DE, Engel F, Longerich T, Koo BK, Koch M, Delhomme N, et al. Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain. Gut 2010;59: 1236-44.
38. Kosinski C, Li VS, Chan AS, Zhang J, Ho C, Tsui WY, et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad SciUS A 2007;104:15418-23.
39. Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer H, et al. Transcriptome profile of human colorectal adenomas. Mol Cancer Res 2007;5:1263-75.
40. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010;138:2101-14 e5.
41. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001;61:3573-7.
42. Chiba T, Marusawa H, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 2012;143: 550-63.
43. Planell N, Lozano JJ, Mora-Buch R, Masamunt MC, Jimeno M, Ordas I, et al. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut 2013;62:967-76.
44. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009;457:608-11.
45. Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, Ziegler PK, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013;152:25-38.
46. Shih IM, Wang TL, Traverso G, Romans K, Hamilton SR, Ben-Sasson S, et al. Top-down morphogenesis of colorectal tumors. Proc Natl Acad Sci U S A 2001;98:2640-5.
47. Beerman I, Bock C, Garrison BS, Smith ZD, Gu H, Meissner A, et al. Proliferation-dependent alterations of the DNA methylation landscape underlie hematopoietic stem cell aging. Cell Stem Cell 2013;12: 413-25.
48. Maegawa S, Hinkal G, Kim HS, Shen L, Zhang L, Zhang J, et al. Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res 2010;20:332-40.
49. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, et al. The polycomb group proteins bind throughout the Ink4a-Arf locus and are disassociated in senescent cells. Genes Dev 2007;21:525-30.
50. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. Ezh2 is downstream of the PRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323-35.
51. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.